HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug
Hui Ding(Cedars-Sinai Medical Center), Eggehard Holler(Terasaki Foundation), Anna Galstyan(Cedars-Sinai Medical Center), Paul A. Hubbard(Cedars-Sinai Medical Center), Ramachandran Murali(The Wistar Institute), Rameshwar Patil(Cedars-Sinai Medical Center), Julia Y. Ljubimova(Cedars-Sinai Medical Center), Pallavi R. Gangalum(Cedars-Sinai Medical Center), Irving H. Fox(Takeda (United States))
Cited by 40
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694